Nkarta, Inc. products

OX40 costimulatory domain, CD3ζ signaling moiety, membrane bound IL-15.

OX40 costimulatory domain, CD3ζ signaling moiety, membrane bound IL-15.

Cell therapy, a new approach that uses immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. First generation approaches have focused on T-cells, which have shown great promise in hematologic malignancies but are plagued with unwanted side effects and, to date, have not shown similar activity in solid tumors. Nkarta was founded to address these limitations through the application of next generation technologies. NK cells are the body’s first line of defense against viral infections and cancerous cells with an innate ability to rapidly seek and destroy transformed cells.